Compare CDP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | IDYA |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 1996 | 2019 |
| Metric | CDP | IDYA |
|---|---|---|
| Price | $33.55 | $34.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $39.75 | ★ $52.75 |
| AVG Volume (30 Days) | ★ 834.6K | 772.4K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | 8.94 | ★ 61.90 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $763,923,000.00 | $218,710,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $3.22 | $191.41 |
| P/E Ratio | $45.47 | ★ N/A |
| Revenue Growth | 1.41 | ★ 3024.43 |
| 52 Week Low | $27.06 | $26.81 |
| 52 Week High | $38.90 | $42.68 |
| Indicator | CDP | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 33.69 |
| Support Level | $33.08 | $33.72 |
| Resistance Level | $34.78 | $35.14 |
| Average True Range (ATR) | 0.61 | 1.43 |
| MACD | 0.07 | -0.28 |
| Stochastic Oscillator | 34.94 | 7.36 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. The company has two reportable segments: Defense/IT Portfolio; and Other. Defense/IT Portfolio includes sub-segments such as: Fort George G. Meade and the Baltimore/Washington Corridor (Fort Meade/BW Corridor); Redstone Arsenal in Huntsville, Alabama; Northern Virginia Defense/IT Locations (NoVA Defense/IT); Lackland Air Force Base in San Antonio, Texas; locations serving the U.S. Navy (Navy Support); and data center shells in Northern Virginia.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.